Compare Enveric Biosciences Inc (ENVB) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Charles Schwab Corporation Common Stock — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while Charles Schwab Corporation Common Stock trades at $102.44 (market cap $178.77B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 33603.4× Enveric Biosciences Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.25% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | SCHW | |
|---|---|---|
Market Cap | $5.32M | $178.77B |
Sector | Health | Financials |
52-Week High | $17.40 | $107.21 |
52-Week Low | $1.28 | $85.35 |
Enterprise Value | $408.82K | — |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Charles Schwab (SCHW) trades at $102.69, up 1.57% recently, with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.43 exceeding the $1.40 estimate, and revenue growth to $23.92B in 2025. Analyst consensus is bullish, with a $123.71 price target implying 20% upside, supported by robust trading activity and net income margins near 38%.
Outlook remains positive due to earnings momentum and favorable interest rate conditions, but risks include market volatility and competitive pressures. The stock's valuation at a P/E of 20.44 is reasonable given high ROE of 21.79%, though debt levels and economic sensitivity warrant monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
